Association of Funding and Conclusions in Randomized Drug Trials

Abstract

Context Previous studies indicate that industry-sponsored trials tend to draw proindustry conclusions. Objective To explore whether the association between funding and conclusions in randomized drug trials reflects treatment effects or adverse events. Design Observational study of 370 randomized drug trials included in metaanalyses from Cochrane reviews selected from the Cochrane Library, May 2001. From a random sample of 167 Cochrane reviews, 25 contained eligible meta-analyses (assessed a binary outcome; pooled at least 5 full-paper trials of which at least 1 reported adequate and 1 reported inadequate allocation concealment). The primary binary outcome from each meta-analysis was considered the primary outcome for all trials included in each meta-analysis. The association between funding and conclusions was analyzed by logistic regression with adjustment for treatment effect, adverse events, and additional confounding factors (methodological quality, control intervention, sample size, publication year, and place of publication). Main Outcome Measure Conclusions in trials, classified into whether the experimental drug was recommended as the treatment of choice or not. Results The experimental drug was recommended as treatment of choice in 16% of trials funded by nonprofit organizations, 30% of trials not reporting funding, 35% of trials funded by both nonprofit and for-profit organizations, and 51% of trials funded by for-profit organizations (PϽ.001; 2 test). Logistic regression analyses indicated that funding, treatment effect, and double blinding were the only significant predictors of conclusions. Adjusted analyses showed that trials funded by for-profit organizations were significantly more likely to recommend the experimental drug as treatment of choice (odds ratio, 5.3; 95% confidence interval, 2.0-14.4) compared with trials funded by nonprofit organizations. This association did not appear to reflect treatment effect or adverse events. Conclusions Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results. Readers should carefully evaluate whether conclusions in randomized trials are supported by data.

Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study

“…[23][24][25][26] Industry studies operate with larger budgets than government-funded or privately-funded studies, enabling them to run more sensitive tests using better equipment. [27][28][29][30] This is in line with our findings.…”

Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics

“…This finding is in accordance with numerous previous reports of a similar effect in other medical fields (3,4,6,69). Even more striking were our findings for pair-wise comparison of different trials that examined the effects of the same two drugs (Table 1).…”

The association of funding source on effect size in randomized controlled trials: 2013–2015 – a cross-sectional survey and meta-analysis

“…Our findings are in line with earlier studies demonstrating an association between for-profit-funded research and a more favorable outcome [1, 3, 5, 15]; however, these studies were based on data published 10–15 years ago. Previous research has been focused on specific medical fields, such as cardiovascular research [3], nutrition [16], or drug trials [5].…”